<DOC>
	<DOCNO>NCT00530920</DOCNO>
	<brief_summary>The purpose study identify optimal dose combination ( ) tipranavir ( TPV ) ritonavir ( RTV ) antiretroviral treatment naïve HIV-1 infect patient use pivotal trial assess steady-state pharmacokinetics short-term efficacy safety</brief_summary>
	<brief_title>Tipranavir/Ritonavir Low Dose Pharmacokinetics Treatment Naive Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<criteria>Signed informed consent accordance GCP local regulatory requirement prior trial participation . HIV1 infect men nonpregnant woman treatment naïve , positive serology ( EIA ) confirm Western blot . Age &gt; 18 &lt; 65 year . CD4 &gt; 200 cells/mm3 Viral load ( HIV1 mRNA viral load ) &gt; 5,000 copies/mL . Ability swallow multiple large capsule without difficulty . Acceptable laboratory value indicate adequate baseline organ function screen visit . Laboratory value consider acceptable severity parameter = &lt; Grade 2 , base DAIDS/ACTG Grading Scale ( see Appendix 10.2 ) . Acceptable medical history , physical examination , 12lead ECG screen Willingness abstain follow start 2 week prior administration study medication end study : Grapefruit grapefruit juice , Seville oranges , St. John 's Wort , Milk Thistle . Willingness abstain alcohol 3 day prior administration study medication end study . Willingness abstain follow start 3 day prior PK sampling : Garlic supplement methylxanthine contain food drink ( include coffee , tea , cola , energy drink , chocolate , etc. ) . Willingness abstain overthecounter herbal medication duration study . Willingness abstain counter medication 7 day prior administration study medication ( include vitamin , mineral , dietary supplement antacid ) study completion post study assessment . Female patient reproductive potential : Have positive serum pregnancy test . Have use barrier method contraception least 3 month prior participation study . Are willing use reliable method barrier contraception ( diaphragm spermicidal cream/jelly condoms spermicidal foam ) , 60 day completion/termination trial . Are breastfeed . Suspected documented seroconversion within last 6 month Participation another trial investigational medicine within 2 month prior Day 0 study . Use pharmacological contraceptive ( include oral , patch injectable contraceptive ) within 1 month prior Day 0 duration study . Use hormone replacement therapy within 1 month prior Day 0 anytime study . History acute illness within 30 day prior Day 0 . Have evidence active acute HBV HCV . Alcohol substance abuse within 1 year prior screen study . Patients history illness allergy , opinion investigator , might confound result study pose additional risk administer TPV . Patients take ( within 7 day prior Day 0 ) overthecounter prescription medication , opinion investigator consultation BI clinical monitor , might interfere absorption , distribution , metabolism study medication . Known hypersensitivity ingredient test drug . Inability adhere protocol . Genotypic resistance tipranavir ( define TPV mutation score &gt; 4 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>